Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 Mar;63(3):485–490.

Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.

M A Epstein, B J Randle, S Finerty, J K Kirkwood
PMCID: PMC1577551  PMID: 3011324

Abstract

Cottontop tamarins have been immunized with a high molecular weight, Epstein-Barr (EB) virus membrane antigen (MA) glycoprotein (gp340) separated by monoclonal antibody immunoaffinity chromatography (MCABgp340). Specific antibody production was monitored by immunofluorescence, a highly sensitive enzyme-linked immunosorbent assay (ELISA), and virus neutralization tests, and was found to reach high titre after 4/5 inoculations. The animals were challenged with a 100% lymphomagenic dose of EB virus but despite possessing powerful neutralizing antibodies were not protected against tumour causation by the virus. This result contrasts with that of earlier experiments in which tamarins with neutralizing antibodies induced by gp340 prepared by a molecular weight-based method (MWgp340) were protected V体育ios版. The reasons for this difference in protection associated with vaccine molecules prepared in different ways are discussed together with the need for parameters other than neutralizing antibody for use in the assessment of subunit immunogens against EB virus.

Full text

PDF
485

Selected References

These references are in PubMed VSports最新版本. This may not be the complete list of references from this article.

  1. Barker L. F., Maynard J. E., Purcell R. H., Hoofnagle J. H., Berquist K. R., London W. T., Gerety R. J., Krushak D. H. Hepatitis B virus infection in chimpanzees: titration of subtypes. J Infect Dis. 1975 Oct;132(4):451–458. doi: 10.1093/infdis/132.4.451. ["V体育官网入口" DOI] [PubMed] [Google Scholar]
  2. Cleary M. L., Epstein M. A., Finerty S., Dorfman R. F., Bornkamm G. W., Kirkwood J. K., Morgan A. J., Sklar J. Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science. 1985 May 10;228(4700):722–724. doi: 10.1126/science.2986287. ["VSports注册入口" DOI] [PubMed] [Google Scholar]
  3. EPSTEIN M. A., ACHONG B. G., BARR Y. M. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA. Lancet. 1964 Mar 28;1(7335):702–703. doi: 10.1016/s0140-6736(64)91524-7. [DOI] [PubMed] [Google Scholar]
  4. Epstein M. A. Epstein-Barr virus--is it time to develop a vaccine program? J Natl Cancer Inst. 1976 Apr;56(4):697–700. doi: 10.1093/jnci/56.4.697. [DOI] [PubMed] [Google Scholar]
  5. Epstein M. A., Morgan A. J. Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine. Clin Exp Immunol. 1983 Aug;53(2):257–271. [PMC free article] [PubMed] [Google Scholar]
  6. Epstein M. A., Morgan A. J., Finerty S., Randle B. J., Kirkwood J. K. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature. 1985 Nov 21;318(6043):287–289. doi: 10.1038/318287a0. [DOI] [PubMed] [Google Scholar]
  7. Epstein M. A. The Leeuwenhoek lecture, 1983. A prototype vaccine to prevent Epstein-Barr virus-associated tumours. Proc R Soc Lond B Biol Sci. 1984 Mar 22;221(1222):1–20. doi: 10.1098/rspb.1984.0019. [DOI] [PubMed] [Google Scholar]
  8. Gergely L., Klein G., Ernberg I. Appearance of Epstein-Barr virus-associated antigens in infected Raji cells. Virology. 1971 Jul;45(1):10–21. doi: 10.1016/0042-6822(71)90107-3. [DOI] [PubMed] [Google Scholar]
  9. Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hoffman G. J., Lazarowitz S. G., Hayward S. D. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980 May;77(5):2979–2983. doi: 10.1073/pnas.77.5.2979. [V体育ios版 - DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hudewentz J., Bornkamm G. W., Zur Hausen H. Effect of the diterpene ester TPA on Epstein-Barr virus antigen- and DNA synthesis in producer and nonproducer cell lines. Virology. 1980 Jan 15;100(1):175–178. doi: 10.1016/0042-6822(80)90563-2. [DOI] [PubMed] [Google Scholar]
  12. Kirkwood J. K., Epstein M. A., Terlecki A. J. Factors influencing population growth of a colony of cotton-top tamarins. Lab Anim. 1983 Jan;17(1):35–41. doi: 10.1258/002367783781070867. [DOI] [PubMed] [Google Scholar]
  13. Kirkwood J. K., Epstein M. A., Terlecki A. J., Underwood S. J. Rearing a second generation of cotton-top tamarins (Saguinus oedipus oedipus) in captivity. Lab Anim. 1985 Oct;19(4):269–272. doi: 10.1258/002367785780887491. [DOI] [PubMed] [Google Scholar]
  14. Klein G., Clifford P., Klein E., Stjernswärd J. Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A. 1966 Jun;55(6):1628–1635. doi: 10.1073/pnas.55.6.1628. [DOI (VSports注册入口)] [PMC free article] [PubMed] [Google Scholar]
  15. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  16. Miller G., Shope T., Lisco H., Stitt D., Lipman M. Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A. 1972 Feb;69(2):383–387. doi: 10.1073/pnas.69.2.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Morgan A. J., Epstein M. A., North J. R. Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins. J Med Virol. 1984;13(3):281–292. doi: 10.1002/jmv.1890130310. ["VSports" DOI] [PubMed] [Google Scholar]
  18. Morgan A. J., North J. R., Epstein M. A. Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form. J Gen Virol. 1983 Feb;64(Pt 2):455–460. doi: 10.1099/0022-1317-64-2-455. [DOI] [PubMed] [Google Scholar]
  19. Moss D. J., Pope J. H. Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol. 1972 Nov;17(2):233–236. doi: 10.1099/0022-1317-17-2-233. ["VSports手机版" DOI] [PubMed] [Google Scholar]
  20. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci U S A. 1982 Dec;79(23):7504–7508. doi: 10.1073/pnas.79.23.7504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. Quantification of an Epstein-Barr virus-associated membrane antigen component. J Virol Methods. 1982 Sep;5(1):55–65. doi: 10.1016/0166-0934(82)90097-0. [DOI (V体育官网)] [PubMed] [Google Scholar]
  22. Pearson G. R., Henle G., Henle W. Production of antigens associated with Epstein-Barr virus in experimentally infected lymphoblastoid cell lines. J Natl Cancer Inst. 1971 Jun;46(6):1243–1250. [VSports注册入口 - PubMed] [Google Scholar]
  23. Randle B. J., Epstein M. A. A highly sensitive enzyme-linked immunosorbent assay to quantitate antibodies to Epstein-Barr virus membrane antigen gp340. J Virol Methods. 1984 Nov;9(3):201–208. doi: 10.1016/0166-0934(84)90026-0. [DOI (V体育平台登录)] [PubMed] [Google Scholar]
  24. Randle B. J., Morgan A. J., Stripp S. A., Epstein M. A. Large-scale purification of Epstein-Barr virus membrane antigen gp340 with a monoclonal antibody immunoabsorbent. J Immunol Methods. 1985 Feb 28;77(1):25–36. doi: 10.1016/0022-1759(85)90180-2. [DOI] [PubMed] [Google Scholar]
  25. Shanmugaratnam K. Studies on the etiology of nasopharyngeal carcinoma. Int Rev Exp Pathol. 1971;10:361–413. [PubMed] [Google Scholar]
  26. Wilson G., Miller G. Recovery of Epstein-Barr virus from nonproducer neonatal human lymphoid cell transformants. Virology. 1979 Jun;95(2):351–358. doi: 10.1016/0042-6822(79)90490-2. ["V体育平台登录" DOI] [PubMed] [Google Scholar]
  27. de Schryver A., Klein G., Hewetson J., Rocchi G., Henle W., Henle G., Moss D. J., Pope J. H. Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti-MA). Int J Cancer. 1974 Mar 15;13(3):353–362. doi: 10.1002/ijc.2910130311. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES